BridgeMD
Compares treatment options for Nasopharyngeal Cancinoma (NPC)
Official title Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
ClinicalTrials.gov ID: NCT06669611
What this study is testing
What is Camrelizumab combined GP chemotherapy?
Camrelizumab combined GP chemotherapy is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for nasopharyngeal cancinoma (npc).
Also referred to as Camrelizumab, cisplatin and gemcitabine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age over 18 years.
- ECOG score of 0-1.
- Expected survival of at least 12 weeks.
- Recurrent/Metastatic Nasopharyngeal Carcinoma.
- At least 4 weeks since the previous chemotherapy.
See the full eligibility criteria
- Age over 18 years.
- ECOG score of 0-1.
- Expected survival of at least 12 weeks.
- Recurrent/Metastatic Nasopharyngeal Carcinoma.
- At least 4 weeks since the previous chemotherapy.
- At least one (according to RECIST) measurable lesion, lesions that have been previously irradiated can not be considered target lesions.
- had adequate organ function
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.